What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese prepubertal children?

Antioxidants and Redox Signaling

Volumn 14, Issue 6, 2011, Pages 1167-1172

  D'Adamo, Ebe ^a   Giannini, Cosimo ^a   Chiavaroli, Valentina ^a   De Giorgis, Tommaso ^a   Verrotti, Alberto ^a   Chiarelli, Francesco ^a   Mohn, Angelika ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ENDOGENOUS SECRETORY RECEPTOR FOR ADVANCED GLYCATION END PRODUCT; SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END PRODUCT; UNCLASSIFIED DRUG;

CHILD; CONTROLLED STUDY; FATTY LIVER; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PREPUBERTY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SHORT SURVEY; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FATTY LIVER; FEMALE; HUMANS; MALE; OBESITY; RECEPTORS, IMMUNOLOGIC; YOUNG ADULT;

EID: 79951908002     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2010.3719     Document Type: Short Survey

References (24)

1. Agarwal N and Sharma BC. Insulin resistance and clinical aspects of nonalcoholic steatohepatitis (NASH). Hepatol Res 33: 92-96, 2005. (Pubitemid 41799782)
2. Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall, 1991, pp. 431-433.
3. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Position statement. Diabetes Care 29: 43-48, 2006.
4. Burgert TS, Taksali SE, Dziura J, Goodman TR, Yeckel CW, Papademetris X, Constable RT, Weiss R, Tamborlane WV, Savoye M, Seyal AA, and Caprio S. Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab 91: 4287-4294, 2006. (Pubitemid 44833400)
5. Cali AM, De Oliveira AM, Kim H, Chen S, Reyes-Mugica M, Escalera S, Dziura J, Taksali SE, Kursawe R, Shaw M, Savoye M, Pierpont B, Constable RT, and Caprio S. Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link? Hepatology 49: 1896-1903, 2009.
6. D'Adamo E, Cali AM, Weiss R, Santoro N, Pierpont B, Northrup V, and Caprio S. Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. Diabetes Care 33: 1817-1822, 2010.
7. D'Adamo E, Impicciatore M, Capanna R, Loredana Marcovecchio M, Masuccio FG, Chiarelli F, and Mohn AA. Liver steatosis in obese prepubertal children: a possible role of insulin resistance. Obesity (Silver Spring) 16: 677-683, 2008. (Pubitemid 351328019)
8. D'Adamo E, Marcovecchio ML, Giannini C, Capanna R, Impicciatore M, Chiarelli F, and Mohn A. The possible role of liver steatosis in defining metabolic syndrome in prepubertal children. Metabolism 59: 671-676, 2010.
9. Ekong U, Zeng S, Dun H, Feirt N, Guo J, Ippagunta N, Guarrera JV, Lu Y, Weinberg A, Qu W, Ramasamy R, Schmidt AM, and Emond JC. Blockade of the receptor for advanced glycation end products attenuates acetaminophen-induced hepatotoxicity in mice. J Gastroenterol Hepatol 21: 682-688, 2006.
10. Fabbrini E, Sullivan S, and Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51: 679-689, 2010.
11. Hyogo H and Yamagishi S. Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des 14: 969-972, 2008. (Pubitemid 351753284)
12. Iwamoto K, Kanno K, Hyogo H, Yamagishi S, Takeuchi M, Tazuma S, and Chayama K. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol 43: 298-304, 2008. (Pubitemid 351650040)
13. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, Emoto M, Shoji T, Tamei H, Matsuki H, Sakurai S, Yamamoto Y, Yonekura H, Watanabe T, Yamamoto H, and Nishizawa Y. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25: 2587-2693, 2005.
14. Koyama H, Yamamoto H, and Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med 13: 625-635, 2007. (Pubitemid 350228723)
15. Loomba R, Sirlin CB, Schwimmer JB, and Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 50: 1282-1293, 2009.
16. Manco M, Marcellini M, Devito R, Comparcola D, Sartorelli MR, and Nobili V. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. Int J Obes 32: 381-387; 2008.
17. Marcovecchio ML, Giannini C, Dalton RN, Widmer B, Chiarelli F, and Dunger DB. Reduced endogenous secretory receptor for advanced glycation end products (esRAGE) in young people with Type 1 diabetes developing microalbuminuria. Diabetes Med 26: 815-819, 2009.
18. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123: 745-750, 2002. (Pubitemid 34977081)
19. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, and Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 118: 1388-1393, 2006. (Pubitemid 46393782)
20. Unoki H and Yamagishi S. Advanced glycation end products and insulin resistance. Curr Pharm Des 14: 987-989, 2008. (Pubitemid 351753287)
21. Vazzana N, Santilli F, Cuccurullo C, and Davì G. Soluble forms of RAGE in internal medicine. Intern Emerg Med 4: 389-401, 2009.
22. Yeckel CW, Weiss R, Dziura J, Taksali SE, Dufour S, Burgert TS, Tamborlane WV, and Caprio S. Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents. J Clin Endocrinol Metab 89: 1096-1110, 2004.
23. Yilmaz Y. The AGEs-RAGE axis and nonalcoholic steatohepatitis: the evidence mounts. J Gastroenterol 45: 782-783, 2010.
24. Yilmaz Y, Ulukaya E, Gul OO, Arabul M, Gul CB, Atug O, Oral AY, Aker S, and Dolar E. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem 42: 802-807, 2009.